
Dianthus Therapeutics (DNTH) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Dianthus Therapeutics in November 2026.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Dianthus Therapeutics (DNTH) Stock Forecast
Analyst price target, next 12 months
$103.80
+16.8% vs today's $88.89
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Dianthus Therapeutics have a consensus 12-month target of $103.80, above the current price of $88.89.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 22 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Diantus Therapeutics' stock with a target price of $103.80, indicating significant growth potential.
Financial Health
Dianthus Therapeutics is generating modest revenue and cash flow but has a strong asset value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.